Investigating how liver signals affect insulin resistance and blood sugar levels
Role of the hepatic GABA shunt in insulin resistance and hyperinsulinemia
This study is looking at how a substance made in the liver called GABA affects insulin resistance and high insulin levels, which are common in type 2 diabetes, to find new ways to help improve blood sugar control for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11060066 on NIH RePORTER |
What this research studies
This research explores the role of a neurotransmitter called GABA produced in the liver and its impact on insulin resistance and hyperinsulinemia, conditions often associated with type 2 diabetes. By examining how liver signaling influences insulin release and glucose clearance, the study aims to identify potential therapeutic targets for improving insulin sensitivity. The approach includes both animal models and clinical trials to assess the effects of manipulating liver GABA levels on metabolic health. Patients may benefit from insights that could lead to new treatments for managing blood sugar levels.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with insulin resistance or type 2 diabetes, particularly those with associated liver conditions.
Not a fit: Patients without insulin resistance or type 2 diabetes, or those with other unrelated metabolic disorders, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve insulin sensitivity and help manage blood sugar levels in patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promising results in targeting liver signaling pathways to improve metabolic health, suggesting that this approach may be viable.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Renquist, Benjamin Jennings — University of Arizona
- Study coordinator: Renquist, Benjamin Jennings
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.